Eton Pharmaceuticals (ETON) Expected to Announce Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON) is expected to be releasing its Q4 2025 results after the market closes on Thursday, March 19th. Analysts expect Eton Pharmaceuticals to post earnings of $0.12 per share and revenue of $20.5790 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:30 PM ET.

Eton Pharmaceuticals Stock Down 0.5%

ETON stock opened at $18.92 on Wednesday. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 1.19. The firm has a 50-day moving average of $16.45 and a two-hundred day moving average of $17.31. Eton Pharmaceuticals has a 12 month low of $11.09 and a 12 month high of $23.00. The company has a market cap of $507.40 million, a price-to-earnings ratio of -75.68 and a beta of 1.19.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Invesco Ltd. lifted its stake in shares of Eton Pharmaceuticals by 46.1% during the fourth quarter. Invesco Ltd. now owns 19,691 shares of the company’s stock valued at $333,000 after buying an additional 6,213 shares during the period. XTX Topco Ltd grew its stake in Eton Pharmaceuticals by 33.3% in the 4th quarter. XTX Topco Ltd now owns 32,527 shares of the company’s stock worth $550,000 after acquiring an additional 8,128 shares during the period. Millennium Management LLC grew its stake in Eton Pharmaceuticals by 400.1% in the 4th quarter. Millennium Management LLC now owns 79,331 shares of the company’s stock worth $1,341,000 after acquiring an additional 63,469 shares during the period. Jump Financial LLC acquired a new position in Eton Pharmaceuticals in the 4th quarter valued at $178,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Eton Pharmaceuticals by 13.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,369 shares of the company’s stock worth $260,000 after purchasing an additional 1,845 shares during the period. Institutional investors and hedge funds own 27.86% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ETON. HC Wainwright increased their price target on Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Zacks Research upgraded Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Craig Hallum lifted their price target on Eton Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Eton Pharmaceuticals currently has an average rating of “Hold” and an average price target of $31.00.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.